Get the Stockscreener App
62.15
0.50%
0.31
Cg Oncology Inc stock is traded at $62.15, with a volume of 233.31K.
It is up +0.50% in the last 24 hours and down -14.33% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$61.84
Open:
$62.7
24h Volume:
233.31K
Relative Volume:
0.26
Market Cap:
$5.51B
Revenue:
$5.07M
Net Income/Loss:
$-186.75M
P/E Ratio:
-26.53
EPS:
-2.3424
Net Cash Flow:
$-160.43M
1W Performance:
-1.75%
1M Performance:
-14.33%
6M Performance:
-8.17%
1Y Performance:
+44.37%
1-Day Range:
$61.65
$63.24
1-Week Range:
$61.27
$65.18
52-Week Range:
$35.80
$80.97
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 409-3700
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare CGON vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
62.15 | 5.51B | 5.07M | -186.75M | -160.43M | -2.3424 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-11-25 | Initiated | Wedbush | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
After $7.9M sale, CG Oncology (NASDAQ: CGON) officer plans more stock trades - Stock Titan
CG Oncology (Nasdaq:CGON)Stock Analysis - Simply Wall Street
CG Oncology (NASDAQ: CGON) director sells shares under preset trading plan - Stock Titan
CGON Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Costs Weigh on Results - careplusvn.com
CGON Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Costs Weigh on ResultsEPS Guidance Update - dars.gov.et
CG Oncology (NASDAQ: CGON) officer sold 100,000 shares and now plans more - Stock Titan
Planned CG Oncology (NASDAQ: CGON) insider sale totals 826 shares - Stock Titan
CG Oncology at Cantor conference: cretostimogene nears key readout By Investing.com - Investing.com Canada
CG Oncology at Cantor conference: cretostimogene nears key readout By Investing.com - Investing.com India
CG Oncology at Cantor conference: cretostimogene nears key readout By Investing.com - Investing.com Nigeria
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)? - Zacks Investment Research
CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run - Yahoo Finance
CG Oncology (CGON) officer to sell 29,630 shares after prior 100K trades - Stock Titan
CG Oncology to Present at Upcoming Investor Conferences in September - manilatimes.net
CG Oncology to Present at Upcoming Investor Conferences in September - marketscreener.com
Morgan Stanley and Cantor Fitzgerald conferences will include talks by CG Oncology’s CEO in New York. - Stock Titan
Bank of New York Mellon Corp Invests $16.58 Million in CG Oncology, Inc. $CGON - marketbeat.com
CG Oncology (NASDAQ: CGON) officer lines up new sale after $7.9M August trades - Stock Titan
CG Oncology (NASDAQ: CGON) holder plans 5,789-share sale from option exercise - Stock Titan
ADAR1 Capital Management LLC Invests $8.43 Million in CG Oncology, Inc. $CGON - MarketBeat
Regulatory Momentum Around Oncolytic Virus Therapy Could Be A Game Changer For CG Oncology (CGON) - sahmcapital.com
CG Oncology (NASDAQ: CGON) officer eyes new sale after $7.9M August stock trade - Stock Titan
CG Oncology (NASDAQ: CGON) officer plans new sale after $7.95M August trade - Stock Titan
RTW INVESTMENTS, LP Boosts CG Oncology Inc (CGON) Stake -- Shares Look 38% Undervalued on GF Value - GuruFocus
Jefferies Group's CG Oncology Inc(CGON) Holding History - GuruFocus
Investigation launched into CG Oncology officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm - PR Newswire
How Investors May Respond To CG Oncology (CGON) Revenue Growth Alongside a Widening Net Loss - simplywall.st
How Investors May Respond To CG Oncology (CGON) Revenue Growth Alongside a Widening Net Loss - simplywall.st
CG Oncology (NASDAQ: CGON) insider flags $7.95M stock sale after recent disposals - Stock Titan
CG Oncology stock hits all-time high of 79.5 USD By Investing.com - Investing.com Nigeria
CG Oncology stock hits all-time high of 79.5 USD By Investing.com - Investing.com Canada
CG Oncology stock hits all-time high of 79.5 USD By Investing.com - Investing.com South Africa
CG Oncology stock hits all-time high of 79.5 USD By Investing.com - Investing.com South Africa
CG Oncology stock hits all-time high of 79.5 USD - Investing.com
CG Oncology (NASDAQ:CGON) Flaunts a Perfect Technical Breakout Setup - ChartMill
CG (CGON) Financial Update: EPS Misses Its Estimate in the Reported Period; Share Move: The Stock Ends Up 5.75% at the CloseQuarterly Earnings - careplusvn.com
CG Oncology director sells 1,000 shares at $74.54 | CGON Insider Trading - Stock Titan
CG Oncology (NASDAQ: CGON) insider lines up new stock sale - Stock Titan
CGON shareholder (NASDAQ: CGON) details planned 19,364-share stock sale - Stock Titan
CG Oncology (CGON) sees Foresite Capital report 4.9% beneficial stake via funds - Stock Titan
CG Oncology (CGON): RTW Investments takes 9.7% position, holding 8.5M shares - Stock Titan
CG Oncology's bladder cancer drug shows strong results with 75% response rate and no severe side effects. - Pluang
CG Oncology: Circling Back After Huge Rally - Seeking Alpha
CGON (CGON) investor lists 25,989-share sale after series of stock disposals - Stock Titan
CG Oncology (CGON) Falls 2.96% as Shares Approach Key Support at $70.97Institutional Volume - Vinanet
CG Oncology (CGON): Wellington group discloses 5.3M-share, 6.04% ownership position - Stock Titan
CG Oncology (CGON) Falls 2.96% as Shares Approach Key Support at $70.97Rounding Bottom - siam.in
Truist Financial Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $85 - Moomoo
CGON (NASDAQ: CGON) holder files to sell 32,137 shares after option exercise - Stock Titan
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cg Oncology Inc Stock (CGON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AMBAW BELLETE | Officer |
Sep 17 '26 |
Proposed Sale |
76.50 |
6,532 |
499,698 |
0 |
| POST LEONARD E | Director |
Sep 15 '26 |
Option Exercise |
0.60 |
1,000 |
600 |
1,000 |
| POST LEONARD E | Director |
Sep 15 '26 |
Sale |
72.98 |
1,000 |
72,980 |
0 |
| AMBAW BELLETE | Officer |
Sep 11 '26 |
Proposed Sale |
75.00 |
826 |
61,950 |
0 |
| AMBAW BELLETE | Officer |
Sep 02 '26 |
Proposed Sale |
77.61 |
29,630 |
2,299,448 |
0 |
| AMBAW BELLETE | Officer |
Aug 31 '26 |
Proposed Sale |
75.50 |
50,000 |
3,775,250 |
0 |
| AMBAW BELLETE | Officer |
Aug 27 '26 |
Proposed Sale |
79.39 |
5,789 |
459,561 |
0 |
| AMBAW BELLETE | Officer |
Aug 25 '26 |
Proposed Sale |
79.55 |
10,551 |
839,338 |
0 |
| AMBAW BELLETE | Officer |
Aug 24 '26 |
Proposed Sale |
79.52 |
5,762 |
458,185 |
0 |
| AMBAW BELLETE | Officer |
Aug 19 '26 |
Proposed Sale |
79.54 |
100,000 |
7,954,105 |
0 |
3.06%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):